Atul Q1 Review – Better-Than-Expected Results; Long Term Story Intact: Systematix

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Atul Ltd.’s Q1 FY22 results were slightly above our estimates with sales/Ebitda/profit after tax growth of 64%/49%/41% y-o-y and down 3%/down 7%/down 5% q-o-q.

Sales were driven by a recovery in the performance chemicals division (up 79% y-o-y, down 8% q-o-q) and continued growth in the life science division (30% y-o-y, 13% q-o-q).

Geography-wise, Atul’s growth was led by export markets (49% of sales) while the domestic market was under pressure due to lockdown-led challenges.

Operating profit margin contracted 90 basis points q-o-q to 21.9% due to lower utilisation of mono-chloro-acetic acid in the first quarter of plant operations, a sharp increase in raw material prices (20-90%) and a decline in the spreads of key products.

Click on the attachment to read the full report:

Systematix Atul Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button